Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

All NICE products on vulnerable groups. Includes any guidance and quality standards.

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.